Physician profile
Robert A Sarro
NPI 1164403192
$26,971.16
in general payments reported to CMS, 2019-2025
26 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,972 · 2020: $318 · 2021: $668 · 2022: $2,230 · 2023: $10K · 2024: $9,585 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $3,334 · Travel and Lodging: $536 · Grant: $220 · Education: $98.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,596.00 |
| Food and Beverage | $3,333.60 |
| Travel and Lodging | $535.71 |
| Grant | $220.00 |
| Education | $98.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $18,507.66 | 2019-2025 | Ilumya |
| Promius Pharma LLC | $2,123.96 | 2019 | |
| Ucb, INC. | $1,269.02 | 2019-2025 | Bimzelx |
| Abbvie INC. | $874.59 | 2019-2025 | Rinvoq |
| Genzyme Corporation | $822.47 | 2023-2025 | |
| Medimetriks Pharmaceuticals, INC. | $700.00 | 2021-2022 | |
| Janssen Biotech, INC. | $597.22 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $388.74 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $331.46 | 2019-2025 | |
| Pfizer INC. | $243.23 | 2022-2025 | |
| Incyte Corporation | $235.47 | 2022-2025 | Opzelura |
| Strata Skin Sciences, INC. | $207.73 | 2019-2025 | Xtrac |
| Galderma Laboratories, L.P. | $117.60 | 2019-2025 | Nemluvio, Oracea, Epsolay |
| Vyne Pharmaceuticals INC. | $98.69 | 2020-2021 | |
| Dermavant Sciences, INC. | $88.29 | 2022-2024 | Vtama |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $87.89 | 2023-2024 | Zoryve |
| Almirall LLC | $65.85 | 2022-2025 | Klisyri |
| Leo Pharma INC. | $45.11 | 2022-2024 | Adbry |
| Amgen INC. | $39.09 | 2024 | Otezla |
| Lnhc, INC | $36.77 | 2025 | Zelsuvmi |
| Lilly USA, LLC | $24.97 | 2025 | Ebglyss |
| Nabriva Therapeutics, Plc | $20.26 | 2022 | |
| Verrica Pharmaceuticals INC. | $16.09 | 2025 | Ycanth |
| Allergan, INC. | $15.13 | 2022 | |
| Mayne Pharma Commercial LLC | $13.87 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sarro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.